Anti-Schistosomiasis Sm14-vaccine in Senegal
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05658614 |
Recruitment Status :
Recruiting
First Posted : December 21, 2022
Last Update Posted : December 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Previous clinical trials have already demonstrated the safety of the candidate vaccine in adults as well as in children, in good health or infected with schistosomiasis. Regarding the induced immune response, more than 80% of vaccinated subjects were seroconverted after three vaccine injections. The induced immune response was substantial but transient. In order to obtain a more lasting immune response, the investigator will experiment with a new vaccination schedule (2 injections 1-month interval and the 3rd injection 5 months after the first dose), versus the vaccine schedule initially used (3 injections at 1-month interval).
This trial will be the last phase 2 before testing the efficacy of the rSm14 vaccine candidate.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schistosomiasis Mansoni Schistosomiasis Haematobium Vaccination; Infection | Biological: Sm14 recombinant vaccine+ GLA-SE adjuvant | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Main objective: to compare the immunological quality of the new vaccination schedule (amplitude and duration) versus the vaccination schedule used in the previous trials, by studying the Sm14 specific antibody response induced both quantitatively and qualitatively. The hypothesis is to obtain a mean response quantitatively higher with the new vaccine schedule. Secondary objective: safety profile of the two vaccine schedules studied. |
Masking: | None (Open Label) |
Masking Description: | open label |
Primary Purpose: | Prevention |
Official Title: | Evaluation of Immunogenicity and Safety of a New Vaccine Schedule Using the Vaccine Candidate Sm14 Against Schistosomiasis in Adults With a History of S. Mansoni and / or S. Haematobium Infection. |
Actual Study Start Date : | July 1, 2022 |
Estimated Primary Completion Date : | September 15, 2023 |
Estimated Study Completion Date : | December 31, 2023 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm 1 (Group Vacc3)
Volunteers will receive three (3) intramuscular injections into the deltoid muscle of 0.5mL of of the Sm14+ GLA-SE vaccine on D0, W4 and W8. (D = Day; W = Week). (Vaccination schedule used in previous phases).
|
Biological: Sm14 recombinant vaccine+ GLA-SE adjuvant
rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection |
Experimental: Arm 2 (Group Vacc2+1)
Volunteers will receive three (3) intramuscular injections of the Sm14+ GLA-SE vaccine into the deltoid muscle of 0.5mL of vaccine on D0, W4 and W20 (new vaccination schedule).
|
Biological: Sm14 recombinant vaccine+ GLA-SE adjuvant
rSm14 - recombinant protein (GMP produced) - 50ug / injection GLA-SE- synthetic Glucopyranosyl lipid A in stable emulsion: 2.5ug / injection |
- assessment of Immunogenicity 1 [ Time Frame: Day 1 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 2 [ Time Frame: Day 56 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 3 [ Time Frame: Day 84 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 4 [ Time Frame: Day 140 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 5 [ Time Frame: Day 168 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 6 [ Time Frame: Day 224 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 7 [ Time Frame: Day 308 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of Immunogenicity 8 [ Time Frame: Day 392 ]The anti-Sm14 IgG isotypes (Total IgG; IgG1; IgG3; IgG4; IgE) antibody response using an indirect ELISA
- assessment of immunogenicity 9 [ Time Frame: Day 1 ]Measure expression change in membrane markers expression of PBMC under in vitro Sm14 antigen activation
- assessment of immunogenicity 10 [ Time Frame: Day 84 ]Measure expression change in membrane markers expression of PBMC under in vitro Sm14 antigen activation (for Group Vacc3)
- assessment of immunogenicity 11 [ Time Frame: Day 168 ]Measure expression change in membrane markers expression of PBMC under in vitro Sm14 antigen activation (for Group Vacc2+1)
- assessment of immunogenicity 12 [ Time Frame: Day 1 ]12. Measure cytokine production (ELISA) by PBMC under in vitro Sm14 antigen activation
- assessment of immunogenicity 13 [ Time Frame: Day 84 ]12. Measure cytokine production (ELISA) by PBMC under in vitro Sm14 antigen activation (for Group Vacc3)
- assessment of immunogenicity 14 [ Time Frame: Day 168 ]12. Measure cytokine production (ELISA) by PBMC under in vitro Sm14 antigen activation (for Group Vacc2+1)
- Safety of the vaccine candidate Sm14 -1 [ Time Frame: from Day 1 to Day 442 ]The occurrence of study vaccine-related SAEs
- Safety of the vaccine candidate Sm14 - 2 [ Time Frame: from Day 1 to Day 3 ]2. The occurrence of solicited injection site reactogenicity
- Safety of the vaccine candidate Sm14 -3 [ Time Frame: from Day 28 to Day 30 ]The occurrence of solicited injection site reactogenicity
- Safety of the vaccine candidate Sm14 -4 [ Time Frame: from Day 56 to Day 58 ]The occurrence of solicited injection site reactogenicity for Group Vacc3
- Safety of the vaccine candidate Sm14 -5 [ Time Frame: from Day 140 to Day 142 ]The occurrence of solicited injection site reactogenicity for Group Vacc2+1
- Safety of the vaccine candidate Sm14 _6 [ Time Frame: from Day 1 to Day 3 ]The occurrence of solicited injection site reactogenicity
- Safety of the vaccine candidate Sm14 -7 [ Time Frame: from Day 28 to Day 30 ]The occurrence of solicited injection site reactogenicity
- Safety of the vaccine candidate Sm14 -8 [ Time Frame: from Day 56 to Day 58 ]The occurrence of solicited injection site reactogenicity for Group Vacc3
- Safety of the vaccine candidate Sm14 -9 [ Time Frame: from Day 140 to Day 142 ]The occurrence of solicited injection site reactogenicity for Group Vacc2+1
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 49 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Man living in villages in the Saint Louis region where schistosomiasis is endemic.
- Having an infectious history of schistosomiasis.
- Adult between 18 and 49 years old at the time of the first injection.
- Have received pre-treatment with PZQ four to eight weeks before inclusion.
- Consent signed by the volunteer after information.
- Satisfactory state of health, confirmed on clinical examination and following biological assessment (Vpi / W-1).
- Available for the duration of the trial.
- To be negative to the Covid-19 antigenic test
Exclusion Criteria (Non inclusion criteria) :
- Subject not meeting one of the inclusion criteria.
- Participation to a previous anti-schistosomiasis vaccine clinical trial.
- Participation in another ongoing clinical research
- Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immune modulating drugs.
- Known hypersensitivity to any component present in the Sm14 vaccine, or to any given vaccine, and / or history of allergic disease.
- Acute illness at the time of inclusion.
- Other conditions which, according to the PI, can potentially represent a danger to the subject to be included.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05658614
Contact: Miriam TENDLER | +55 21 994 417 749 | mtendler@ioc.fiocruz.br | |
Contact: Marilia SIRIANNI | +55 21 2562 1273 | sirianni@ioc.fiocruz.br |
Senegal | |
Biomedical Research Center EPLS | Recruiting |
Saint Louis, Senegal | |
Contact: Gilles RIVEAU, PharmD PhD +221 774228826 gilles.riveau@gmail.com | |
Contact: Anne-Marie SCHACHT, MS +221 339610377 am.schacht@gmail.com | |
Principal Investigator: Abdoulaye MBENGUE, MD | |
Sub-Investigator: Amadou Tidjani LY, MD |
Study Director: | Gilles RIVEAU, PharmD PhD | Biomedical Research Center EPLS |
Responsible Party: | MIRIAM TENDLER, MD, PhD, Oswaldo Cruz Foundation |
ClinicalTrials.gov Identifier: | NCT05658614 |
Other Study ID Numbers: |
Sm14-2c-Sn |
First Posted: | December 21, 2022 Key Record Dates |
Last Update Posted: | December 21, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Infections Schistosomiasis Schistosomiasis mansoni Schistosomiasis haematobia Trematode Infections Helminthiasis Parasitic Diseases |
Vector Borne Diseases Urinary Tract Infections Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases |